Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Ciltacabtagene autoleucel (multiple myeloma, at least one prior therapy) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A24-116
Last updated

Report documents

  1. Extract of dossier assessment

    Ciltacabtagene autoleucel (multiple myeloma, at least one prior therapy) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 843 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-116_en
    Download file : Extract of dossier assessment (PDF document, 843 kB, EN, not accessible)

  2. Dossier assessment

    Ciltacabtagene autoleucel (multiple myeloma, at least one prior therapy) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-116
    Download file : Dossier assessment (PDF document, 2 MB, DE, not accessible)

Dossier assessment

Indication:

Adults with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide

Result of dossier assessment:
  • Patients with 1 to 3 prior therapies for whom daratumumab in combination with pomalidomide and dexamethasone (DPd) or pomalidomide in combination with bortezomib and dexamethasone (PVd) is a suitable individualized therapy: hint of a non-quantifiable added benefit
  • Patients with 1 to 3 prior therapies for whom DPd or PVd is not a suitable individualized therapy, and patients with ≥ 4 prior therapies: added benefit not proven

Project details

Project no.
A24-116
Commission
Commission awarded on 29.11.2024 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A24-116_en

Connected Projects

  1. Dossier assessment

    Ciltacabtagene autoleucel (multiple myeloma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V

    Project no.
    G23-04
    Last updated

    Status: Commission completed

  2. Addendum

    Ciltacabtagene autoleucel (multiple myeloma) – Addendum to Project A24-116

    Project no.
    A25-48
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page